233.87
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ABBV?
Forum
Prognose
Dividendenhistorie
Abbvie Inc Aktie (ABBV) Neueste Nachrichten
Is AbbVie’s 30% 2025 Surge Justified by Its Latest Drug Pipeline Wins? - Yahoo Finance
AbbVie Gets FDA Approval for Epkinly Combo for Relapsed Follicular Lymphoma - MarketScreener
AbbVie Announces U.S. FDA Approval of EPKINLY® in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma - Investing News Network
FDA approves AbbVie’s EPKINLY combination therapy for lymphoma By Investing.com - Investing.com Canada
FDA Approves AbbVie's EPKINLY for Follicular Lymphoma Treatment - GuruFocus
FDA Expands Approval for AbbVie's (ABBV) Epkinly in Lymphoma Tre - GuruFocus
AbbVie, Genmab win FDA label expansion for Epkinly (GMAB) - Seeking Alpha
Here's How Neuroscience Drugs Aided AbbVie's Top-line Growth in Q3 - Yahoo Finance
Will AbbVie Inc. stock announce special dividendGap Up & Free Technical Confirmation Trade Alerts - newser.com
AbbVie's (NYSE:ABBV) Dividend Will Be Increased To $1.73 - simplywall.st
Analyst recommendations: Alphabet, Amazon, Microsoft, AbbVie, Comcast… - MarketScreener
How AbbVie Inc. stock performs in easing cycles2025 Earnings Surprises & Stepwise Trade Signal Implementation - newser.com
Enanta Pharmaceuticals Q4 revenue rises, helped by higher sales of AbbVie's MAVYRET/MAVIRET - TradingView
A Look Into AbbVie Inc's Price Over Earnings - Benzinga
AbbVie (ABBV) Gains Health Canada Approval for New Lupron Depot Dosage - GuruFocus
AbbVie Stock Falls 4% -- What Investors Need to Know - Finviz
LUPRON DEPOT® new strength receives Health Canada Approval for the Treatment of Advanced Prostate Cancer - Investing News Network
Filmmaker helps AbbVie spread the word about leukaemia - pharmaphorum
This Sector Is Suddenly Crushing the Broader Market. Should You Invest $1,000? - The Motley Fool
Is AbbVie Inc. reversing from oversold territory2025 Key Lessons & Smart Money Movement Tracker - newser.com
Why AbbVie Inc. stock appears on watchlists2025 Market WrapUp & Daily Price Action Insights - newser.com
Is AbbVie Inc. (4AB) stock a buy before earnings resultsWeekly Profit Recap & Free Long-Term Investment Growth Plans - newser.com
Can AbbVie Inc. (Common Stock) (4AB0) stock retain market dominance2025 Year in Review & Growth Oriented Trade Recommendations - newser.com
Analyzing AbbVie Inc. with risk reward ratio chartsWeekly Stock Summary & Daily Stock Trend Reports - newser.com
Will AbbVie Inc. stock attract more institutional investorsJuly 2025 Earnings & Long Hold Capital Preservation Tips - newser.com
How AbbVie Inc. stock trades before earningsJuly 2025 Selloffs & Detailed Earnings Play Strategies - newser.com
Is AbbVie Inc. (4AB) stock undervalued after correctionJuly 2025 Spike Watch & Growth Focused Stock Reports - newser.com
AbbVie (NYSE:ABBV) Is Increasing Its Dividend To $1.73 - Yahoo Finance
How AbbVie Inc. (Common Stock) (4AB0) stock performs during market turbulenceJuly 2025 Analyst Calls & Daily Stock Trend Watchlist - newser.com
How reliable is AbbVie Inc. (4AB) stock dividend growthJuly 2025 PostEarnings & Consistent Return Investment Signals - newser.com
AbbVie Inc 4AB Stock Analysis and ForecastMarket Liquidity Analysis & Learn the Secrets of Pro Traders - earlytimes.in
How higher bond yields impact AbbVie Inc. stockTrade Volume Summary & Fast Exit and Entry Trade Guides - newser.com
Will AbbVie Inc. stock beat EPS estimates2025 Top Gainers & Reliable Price Breakout Alerts - newser.com
AbbVie Partners with Award-Winning Filmmaker on Film About the Dynamic and Resilient Lives of Those Living with Blood Cancer - Investing News Network
AbbVie (NYSE: ABBV) debuts Second Winds CLL film; YouTube, Documentary+ in Dec 2025 - Stock Titan
Mubadala Investment Co PJSC reports share stake in Adobe, Verizon, dissolves in RTX, AbbVie - MarketScreener
Abbvie describes new LPAR1 antagonists - BioWorld MedTech
Is AbbVie Inc 4AB a good long term investmentExit Strategy Tips & Discover High-Return Stocks Before They Boom - earlytimes.in
AbbVie exits $1.5 billion longevity drug deal with Calico: report - Crain's Chicago Business
Why millennials buy AbbVie Inc. (Common Stock) (4AB0) stockQuarterly Profit Review & High Accuracy Buy Signal Tips - newser.com
Can AbbVie Inc. stock sustain revenue growthEarnings Growth Report & Stepwise Swing Trade Plans - newser.com
The Fight to Save the $2.7 Billion Botox Empire - Bloomberg.com
Is AbbVie Inc. stock undervalued vs historical averages2025 Geopolitical Influence & Proven Capital Preservation Methods - newser.com
Is AbbVie Inc. stock undervalued at current price2025 Technical Overview & Daily Stock Trend Watchlist - newser.com
Why AbbVie Inc. (4AB) stock stays on top picksWeekly Stock Summary & Consistent Income Trade Recommendations - newser.com
How AbbVie Inc. (4AB) stock benefits from digital adoptionWeekly Investment Recap & Capital Efficient Trading Techniques - newser.com
UCB’s Bimzelx and AbbVie’s Rinvoq Lead in EU5 Psoriatic Arthritis, Ankylosing Spondylitis, and Non-Radiographic Axial Spondyloarthritis Growth - The Manila Times
UCB’s Bimzelx and AbbVie’s Rinvoq Lead in EU5 Psoriatic - GlobeNewswire
What Wall Street predicts for AbbVie Inc. stock pricePortfolio Gains Summary & Reliable Price Breakout Alerts - newser.com
Argus Raises AbbVie's Price Target to $250 From $220 - MarketScreener
Can momentum traders help lift AbbVie Inc.IPO Watch & Consistent Growth Stock Picks - newser.com
AbbVie Announces 20 Recipients of Migraine Career Catalyst Award - Investing News Network
Here Are Thursday’s Top Wall Street Analyst Research Calls: AbbVie, AppLovin, Autozone, Booking Holdings, CoreWeave, DoorDash, and More - MSN
AbbVie ends 11-year relationship with Calico, lays off 100+ - PharmaLive
AbbVie Ends 11-Year Relationship With Calico, Lays Off 100+ - BioSpace
AbbVie Announces 20 Recipients of Migraine Career Catalyst Award™ - Yahoo Finance
AbbVie exits alliance with Alphabet biotech Calico; report - pharmaphorum
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):